

ERVK-21 Blocking Peptide (Center)

Synthetic peptide Catalog # BP22081c

Specification

ERVK-21 Blocking Peptide (Center) - Product Information

Primary Accession

P61565 Other Accession

0902F9, 042043, 071037, P61566, P61570, Q9HDB8, Q69384, P61567, Q902F8, Q9UKH3,

P63135

ERVK-21 Blocking Peptide (Center) - Additional Information

Other Names

Endogenous retrovirus group K member 21 Env polyprotein, EnvK1 protein, Envelope polyprotein, HERV-K 12q14.1 provirus ancestral Env polyprotein, Surface protein, SU, Transmembrane protein, TM, ERVK-21

Target/Specificity

The synthetic peptide sequence is selected from aa 291-302 of HUMAN ERVK-21

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

ERVK-21 Blocking Peptide (Center) - Protein Information

Name ERVK-21

Function

Retroviral envelope proteins mediate receptor recognition and membrane fusion during early infection. Endogenous envelope proteins may have kept, lost or modified their original function during evolution. This endogenous envelope protein has lost its original fusogenic properties.

Cellular Location

[Transmembrane protein]: Cell membrane; Single-pass type I membrane protein [Endogenous retrovirus group K member 21 Env polyprotein]: Virion

ERVK-21 Blocking Peptide (Center) - Protocols



Tel: 858.875.1900 Fax: 858.875.1999

Provided below are standard protocols that you may find useful for product applications.

• Blocking Peptides

ERVK-21 Blocking Peptide (Center) - Images

ERVK-21 Blocking Peptide (Center) - Background

Retroviral envelope proteins mediate receptor recognition and membrane fusion during early infection. Endogenous envelope proteins may have kept, lost or modified their original function during evolution. This endogenous envelope protein has lost its original fusogenic properties.

ERVK-21 Blocking Peptide (Center) - References

Scherer S.E., et al. Nature 440:346-351(2006). de Parseval N., et al. J. Virol. 77:10414-10422(2003). Blaise S., et al. Proc. Natl. Acad. Sci. U.S.A. 100:13013-13018(2003). Wang-Johanning F., et al. Oncogene 22:1528-1535(2003).